OL-108

N/A

Report date: 2025/08/01 20:01:42

Base Information

Drug NameOL-108
Drug Alias NameOL-108
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOverland Therapeutics (US) Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeijing GoBroad Hospital
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A